News Archive
Seattle biotech startup born out of a Roche buyout lands $93M to advance therapies
GeekWire
Nov 15, 2022
Media
After $250M Roche buyout, a startup plans a second strike with fresh funding
BioPharmaDive
Nov 15, 2022
Media
From Good to Great: Bonum Therapeutics Raises $93M Series A with Allosterically Regulated Medicines
Genetic Engineering & Biotechnology News
Nov 15, 2022
Media
The crew that sold its lead IL-2 program to Roche is back with $93M to work on more next-gen I/O drugs
Endpoints News
Nov 15, 2022
Media
Roche-backed Bonum bags $93M series A to develop new class of conditionally active therapies
Fierce Biotech
Nov 15, 2022
Media
Good Therapeutics’ Offshoot Bonum Launches with $93 Million in Series A (Updated)
BioSpace
Nov 15, 2022
Media
Bonum Therapeutics Announces a $93M Series A Financing to Advance a Novel and Validated Class of Conditionally Active Therapies
“We believe that this technology has broad potential and we are excited to apply it in new areas…”